Ascentage Pharma Group International (NASDAQ:AAPG) Sees Unusually-High Trading Volume – Still a Buy?

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) saw unusually-high trading volume on Wednesday . Approximately 9,073 shares changed hands during mid-day trading, an increase of 131% from the previous session’s volume of 3,931 shares.The stock last traded at $20.41 and had previously closed at $20.13.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on AAPG shares. China Intl Cap upgraded Ascentage Pharma Group International to a “strong-buy” rating in a research report on Monday, April 6th. BTIG Research restated a “buy” rating and issued a $48.00 price target on shares of Ascentage Pharma Group International in a research report on Monday, April 13th. Finally, Deutsche Bank Aktiengesellschaft started coverage on Ascentage Pharma Group International in a research report on Friday, April 24th. They issued a “buy” rating and a $40.00 price target for the company. Two analysts have rated the stock with a Strong Buy rating and six have assigned a Buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $46.67.

Ascentage Pharma Group International Stock Up 2.2%

The business has a 50-day moving average of $23.31 and a 200-day moving average of $25.98. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.79 and a quick ratio of 1.77.

Ascentage Pharma Group International (NASDAQ:AAPG) last issued its quarterly earnings results on Wednesday, March 25th. The company reported ($0.52) earnings per share (EPS) for the quarter. The company had revenue of $24.72 million during the quarter. On average, sell-side analysts anticipate that Ascentage Pharma Group International – Unsponsored ADR will post -1.09 earnings per share for the current fiscal year.

Institutional Trading of Ascentage Pharma Group International

Institutional investors and hedge funds have recently made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Ascentage Pharma Group International during the third quarter worth $96,000. ABC Arbitrage SA bought a new stake in shares of Ascentage Pharma Group International during the third quarter worth $204,000. XY Capital Ltd lifted its position in shares of Ascentage Pharma Group International by 224.2% during the third quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock worth $707,000 after purchasing an additional 12,530 shares during the last quarter. Citadel Advisors LLC bought a new stake in shares of Ascentage Pharma Group International during the third quarter worth $383,000. Finally, UBS Group AG lifted its position in shares of Ascentage Pharma Group International by 149.4% during the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock worth $716,000 after purchasing an additional 10,988 shares during the last quarter.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.